Your browser doesn't support javascript.
loading
Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients.
Kutney, Katherine; Donnola, Shannon B; Flask, Chris A; Gubitosi-Klug, Rose; O'Riordan, MaryAnn; McBennett, Kimberly; Sferra, Thomas J; Kaminski, Beth.
Afiliação
  • Kutney K; Department of Pediatric Endocrinology, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, United States.
  • Donnola SB; Department of Radiology Case Western Reserve University, Cleveland, OH 44106, United States.
  • Flask CA; Department of Radiology Case Western Reserve University, Cleveland, OH 44106, United States.
  • Gubitosi-Klug R; Department of Pediatric Endocrinology, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, United States.
  • O'Riordan M; Department of Pediatric Endocrinology, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, United States.
  • McBennett K; Department of Pediatric Endocrinology, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, United States.
  • Sferra TJ; Department of Pediatric Endocrinology, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, United States.
  • Kaminski B; Department of Pediatric Endocrinology, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, United States.
World J Hepatol ; 11(12): 761-772, 2019 Dec 27.
Article em En | MEDLINE | ID: mdl-31966908
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2019 Tipo de documento: Article